Director Investor Relations & Communications

Peptilogics adds former DePuy Synthes U.S. President Tim Czartoski to board. August 18, 2026 Tim Czartoski Peptilogics has appointed veteran orthopedic executive Tim Czartoski to its board of directors as the surgical therapeutics company advances zaloganan, its lead drug candidate for treating prosthetic joint infections and other potential medical device-related infections. Czartoski previously served as president of DePuy Synthes U.S. and most recently was president of U.S. Surgical and Global R&D at Enovis. His appointment gives Peptilogics additional commercial and orthopedic operating experience as zaloganan, also known as PLG0206, progresses through the RETAIN Phase 2/3 registration trial for prosthetic joint infection, or PJI. The company is developing zaloganan as a broad-spectrum anti-biofilm drug intended to address infections associated with implanted medical devices. Peptilogics describes the candidate as first-in-class and sees PJI as the initial indication within a larger medical device-related infection market. Czartoski spent 22 years at DePuy Synthes, part of Johnson & Johnson, where he led the company's $5.4 billion U.S. orthopedics business spanning joint reconstruction, trauma, spine, sports medicine and craniomaxillofacial products. His experience also includes launches of robotic technology platforms and advanced knee systems. That background is relevant to Peptilogics as it considers how a drug-based approach to device-related infection could fit into existing orthopedic procedures. Commercializing a surgical therapeutic requires more than demonstrating clinical performance; adoption can also depend on how the treatment integrates with established surgical workflows, hospital practices and the decision-making of orthopedic surgeons. "Infection is the most significant, unsolved problem in orthopedics, and I've spent my career watching surgeons challenged to address them and the persistent biofilm with the tools available," Czartoski said. "Devices alone aren't going to solve this." Prosthetic joint infections present a particularly difficult operational and clinical problem because bacteria can form biofilms on implanted devices. Peptilogics is developing zaloganan to target that underlying infection environment, potentially providing a therapeutic component alongside the surgical approaches used to manage infected implants. "The only real tool surgeons have had against device-related infections is more surgery. We are aiming to change that with zaloganan, and Tim is going to help us change it," Peptilogics CEO Jonathan Steckbeck, Ph.D., said. Steckbeck pointed to Czartoski's experience managing major orthopedic product launches and navigating changes in surgical practice as important capabilities for the company as its clinical program moves forward. For Peptilogics, that experience could become increasingly relevant if zaloganan advances toward commercialization. Introducing a therapeutic into orthopedic infection management would require coordination across drug delivery, surgical procedures and hospital workflows, along with engagement from clinicians accustomed to addressing device-related infections primarily through surgical intervention. Following his career at DePuy Synthes, Czartoski joined Enovis, where his responsibilities included U.S. Surgical operations and global research and development. Across those roles, he has worked on both the commercial and product-development sides of orthopedic care. Czartoski holds a Master of Science in Technology Management from Columbia University, an MBA from the University of Notre Dame and a bachelor's degree from The Ohio State University. He also serves as a volunteer board director at Matthew 25, a nonprofit clinic providing free healthcare to people unable to afford insurance in his community. Peptilogics is focused on developing therapeutics to treat and prevent medical device-related infections. Zaloganan is currently its lead candidate, with the ongoing RETAIN Phase 2/3 registration trial evaluating the drug in PJI. Adding Czartoski to the board brings experience from large-scale orthopedic device businesses into Peptilogics at a stage when the company is working to translate its clinical program into a potential treatment that can function within established surgical practice. That intersection of drug development, orthopedic workflows and commercialization will be central as the company advances zaloganan and evaluates additional applications in medical device-related infections.

Former president of DePuy Synthes U.S. Joins Peptilogics board. Tim Czartoski's appointment reinforces moving beyond the device in orthopedic surgery towards therapeutic treatment of device-related infections Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device businesses, including successful launches of robotic technology platforms and one of the industry's most advanced knee systems, lends significant value to Peptilogics as it moves towards bringing meaningful innovation to market. Czartoski sees tremendous opportunity in therapeutic solutions that advance or complement current approaches to prosthetic joint infections (PJI) and medical device-related infections (MDRI), complications that have been addressed almost exclusively through device and surgical innovation for more than fifty years. PITTSBURGH-(BUSINESS WIRE)-Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device businesses, including successful launches of robotic technology platforms and one of the industry's most advanced knee systems, lends significant value to Peptilogics as it moves towards bringing meaningful innovation to market. Czartoski sees tremendous opportunity in therapeutic solutions that advance or complement current approaches to prosthetic joint infections (PJI) and medical device-related infections (MDRI), complications that have been addressed almost exclusively through device and surgical innovation for more than fifty years. "Infection is the most significant, unsolved problem in orthopedics, and I've spent my career watching surgeons challenged to address them and the persistent biofilm with the tools available. Devices alone aren't going to solve this," said Czartoski. Share "Infection is the most significant, unsolved problem in orthopedics, and I've spent my career watching surgeons challenged to address them and the persistent biofilm with the tools available. Devices alone aren't going to solve this," said Czartoski. "Peptilogics is the first group I've seen approaching the root cause with a drug designed specifically for it, and I wanted to be part of what comes next." "The only real tool surgeons have had against device-related infections is more surgery. We are aiming to change that with zaloganan, and Tim is going to help us change it," said Jonathan Steckbeck, Ph.D., CEO of Peptilogics. "He's led billion-dollar launches at the largest orthopedic companies in the world, and he knows what it takes to change surgical practice. As we move forward, his commercial experience, instincts and relationships will be invaluable." Czartoski is passionate about healthcare and orthopedic innovation. He spent 22 years at DePuy Synthes (Johnson & Johnson), where he led the $5.4B US orthopedics business across Joint Reconstruction, Trauma, Spine, Sports, and CMF. He then served as president of U.S. Surgical and Global R&D at Enovis. He also serves as a volunteer board director at Matthew 25, a non-profit clinic that provides free healthcare to those unable to afford insurance in his local community. He holds an M.S. in Technology Management from Columbia University, an MBA from the University of Notre Dame, and a B.S. from The Ohio State University. About Peptilogics Peptilogics is a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections. The company's lead candidate, zaloganan (PLG0206), is a first-in-class, broad-spectrum anti-biofilm drug candidate currently being evaluated in the RETAIN Phase 2/3 registration trial for the treatment of prosthetic joint infection (PJI), the first of multiple potential indications in the broader medical device-related infection market. For more information, visit www.peptilogics.com. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks, assumptions, and uncertainties. Forward-looking statements are often identified by words such as, but not limited to, "believe," "estimate," "intend," "may," "plan," "potentially," "will," "expect," "enable," "likely," or the negative of these terms or other similar expressions. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans, or Peptilogics, Inc.'s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors. These forward-looking statements are made as of the date of this press release, and Peptilogics, Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contacts. Media Contact: Joe Duraes Pazanga Health Communications [email protected] (917) 687-6419 More News From Peptilogics PITTSBURGH-( BUSINESS WIRE )-Peptilogics, a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections (MDRI), has announced the enrollment of the first patient in the RETAIN Phase 2/3 registration trial by Dr. Toan Le at the University of Cincinnati Medical Center. The trial is evaluating PLG0206, a first-in-class anti-biofilm drug candidate, in patients with prosthetic joint infection (PJI), the first of multiple potential MDRI indications...